The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province

Gastric Cancer Clinical Trial

Official title:

The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03478943
• Other study ID #: Ahead-HAT01
• Status: Active, not recruiting
• Start date: January 30, 2016
• Est. completion date: December 1, 2020

Study information

• Verified date: May 2020
• Source: Henan Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1000
• Est. completion date: December 1, 2020
• Est. primary completion date: August 1, 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patients .

2. Confirmed by Pathology or histology of Gastric cancer.

3. Patients should be voluntary to the trial and provide with signed informed consent.

4. The researchers believe patients can benefit from the study.

Exclusion Criteria:

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories.

2. Pregnant or lactating women.

3. Patients with Apatinib contraindications.

4. Patients of doctors considered unsuitable for the trial.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progress free survival		1 year
Primary	Disease-free surviva		1 year
Secondary	overall survival		3 year
Secondary	Objective Response Rate		1 year
Secondary	Disease Control Rate		1 year